Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale SVP, General Counsel sold 6,404 shares at $1.71 ($10,951)
  2. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 4,361 shares at $1.73 ($7,545)
  3. 4 Open-market sale Chief Technical Officer sold 14,746 shares at $1.71 ($25,216)
  4. 4 Open-market sale President and CEO sold 46,003 shares at $1.68 ($77,285)
  5. 4 Open-market sale EVP of R&D sold 18,832 shares at $1.70 ($32,014)
  6. 4 Grant or award SVP, General Counsel acquired 144,928 shares (grant or award)
  7. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 173,913 shares (grant or award)
  8. 4 Grant or award SVP, Finance acquired 36,232 shares (grant or award)
  9. 4 Grant or award EVP of R&D acquired 173,913 shares (grant or award)
  10. 4 Grant or award Director acquired 369,957 shares (grant or award)
  11. 4 Grant or award President and CEO acquired 552,174 shares (grant or award)
  12. 4 Open-market sale EVP of R&D sold 27,199 shares at $1.78 ($48,414)
  13. 4 Planned sale Director sold 9,136 shares at $2.18 ($19,916)
  14. 4 Open-market sale Director sold 9,221 shares at $2.16 ($19,917)
  15. 4 Shares withheld for taxes CHIEF FINANCIAL OFFICER gave up 36,404 shares (to pay taxes)
  16. 4 Shares withheld for taxes SVP, General Counsel gave up 28,310 shares (to pay taxes)
  17. 4 Planned sale Director sold 18,641 shares at $2.28 ($42,488)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 3 of 14 · 275 filings